Caris Life Sciences (CAI) vs Guardant Health (GH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Guardant Health (GH) has outperformed Caris Life Sciences (CAI) over the past year, gaining 165.3% versus a loss of 14.2%. Guardant Health is the larger company by market cap ($22.02 billion vs $7.55 billion), about 2.9 times the size, while Caris Life Sciences is growing revenue faster (+97.0% vs +32.9%). Caris Life Sciences converts more of its revenue into profit, with a net margin of -8.4% versus -42.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAI | GH |
|---|---|---|
| Share price | $26.70 | $164.08 |
| Market cap | $7.55B | $22.02B |
| 1-day change | -1.48% | -2.52% |
| YTD return | +0.44% | +64.80% |
| 1-year return | -14.19% | +165.34% |
| 5-year return | — | +65.68% |
| P/E ratio (TTM) | 15.80 | — |
| Forward P/E | 72.51 | — |
| EPS (TTM) | $1.69 | $-3.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $812.03M | $982.02M |
| Revenue growth (YoY) | +96.97% | +32.88% |
| Net income (latest FY) | $-68.09M | $-416.28M |
| Gross margin | — | 64.46% |
| Operating margin | 5.56% | -44.53% |
| Net margin | -8.38% | -42.39% |
| 52-week high | $33.65 | $191.05 |
| 52-week low | $14.19 | $61.00 |
| Distance from 52-week high | -20.65% | -14.12% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +8.91% | +21.79% |
| Average volume | 4.93M | 2.02M |
| Shares outstanding | 282.68M | 134.20M |
| Employees | 1,846 | 2,490 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Guardant Health is about 2.9 times larger than Caris Life Sciences by market value ($22.02B vs $7.55B).
- GH has outperformed CAI by 179.5 percentage points over the past year.
- Caris Life Sciences is more profitable, keeping -8.4 cents of every revenue dollar as net income versus -42.4 cents for Guardant Health.
- Caris Life Sciences grew revenue faster in its latest fiscal year (+96.97% vs +32.88%).
About Caris Life Sciences
CAI stock →Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Health Care · Medical Specialities · 1,846 employees
About Guardant Health
GH stock →Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.
Health Care · Medical Specialities · 2,490 employees
CAI vs GH FAQ
Which is bigger, Caris Life Sciences or Guardant Health?
Guardant Health (GH) is larger, with a market capitalization of $22.02B compared with $7.55B for Caris Life Sciences (CAI).
Which stock has performed better over the past year, CAI or GH?
GH returned +165.34% over the past 12 months, compared with -14.19% for CAI (price return, excluding dividends). Past performance does not predict future results.
Are Caris Life Sciences and Guardant Health in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.